This just in from Australia:

PROMISING NEW CANCER TREATMENT FOR DOGS WITH MAST CELL TUMOURS

Results published today reveal QBiotics’ STELFONTA® removes 75% of tumours

The Journal of Veterinary Internal Medicine has today published results from a pivotal canine field study of STELFONTA® (tigilanol tiglate), the lead anticancer pharmaceutical from Australian life sciences company, QBiotics Group Limited (QBiotics).

The study of 123 client-owned dogs demonstrated that in those with Mast Cell Tumours (MCTs), a single intratumoural injection of STELFONTA® removed 75% of MCTs at day 28, significantly higher compared to untreated controls (p<0.001). Further, the trial showed no recurrence in 93% of STELFONTA®-treated dogs at day 84. Importantly, the treatment was well tolerated, and animals had a good quality of life during and after treatment.[1] 

STELFONTA® is a first-in-class pharmaceutical treatment for all grades of MCT now available in Europe with anticipated launches in the USA and Australia, pending approvals.

Dr Chad Johannes, a leading USA veterinary oncologist said, “The study determined STELFONTA® is an efficacious and well-tolerated new option for the local treatment of canine MCT.

“STELFONTA® is administered by injection directly into the tumour. Generally, dogs undergoing treatment do not require sedation or anaesthesia, which carries potential increased risk for older dogs and brachycephalic breeds,” said Dr Johannes. 

READ MORE